FDA Approves First-Line Treatment for Unresectable Triple-Negative Breast Cancer
The FDA has approved Datroway (datopotamab deruxtecan-dlnk), an antibody-drug conjugate (ADC), as the first TROP2-directed therapy for unresectable or metastatic triple-negative breast cancer (TNBC) in patients ineligible for PD-1/PD-L1 inhibitors. ... Read More